AR088989A1 - Derivados biciclicos de dihidroisoquinolin-1-ona - Google Patents
Derivados biciclicos de dihidroisoquinolin-1-onaInfo
- Publication number
- AR088989A1 AR088989A1 ARP120104439A ARP120104439A AR088989A1 AR 088989 A1 AR088989 A1 AR 088989A1 AR P120104439 A ARP120104439 A AR P120104439A AR P120104439 A ARP120104439 A AR P120104439A AR 088989 A1 AR088989 A1 AR 088989A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heterocycloalkyl
- cycloalkyl
- alkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos son útiles para tratar enfermedades renales crónicas hipertensión, aldosterismo primario y síndrome de Cushing. Reivindicación 1: Compuestos de la fórmula (1) en la que: R¹, R², R³ y R⁴ se eligen con independencia entre H, alquilo, cicloalquilo, cicloalquilalquilo, haloalquilo, halocicloalquilo, hidroxialquilo, alcoxialquilo, haloalcoxialquilo, halocicloalquilalquilo, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, arilalquilo sustituido y heteroarilalquilo sustituido, dichos heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, arilalquilo sustituido y heteroarilalquilo sustituido están sustituidos por R¹², R¹³ y R¹⁴; o R² y R⁴ juntos forman un doble enlace, pero en el caso de que R² y R⁴ juntos formen un doble enlace, entonces R⁵ es H; o R¹ y R² junto con el átomo de carbono al que están unidos forman un cicloalquilo sustituido o un heterocicloalquilo sustituido, dichos cicloalquilo sustituido y heterocicloalquilo sustituido están sustituidos por R²², R²³ y R²⁴; o R³ y R⁴ junto con el átomo de carbono al que están unidos forman un cicloalquilo sustituido o un heterocicloalquilo sustituido, dichos cicloalquilo sustituido y heterocicloalquilo sustituido están sustituidos por R²⁹, R³⁰ y R³¹; o R¹ y R³ junto con el átomo de carbono al que están unidos forman un cicloalquilo sustituido o un heterocicloalquilo sustituido, dichos cicloalquilo sustituido y heterocicloalquilo sustituido están sustituidos por R⁴⁴, R⁴⁵ y R⁴⁶; A¹ es CR⁸ o N; A² es CR⁹ o N; A³ es CR¹⁰ o N; A⁴ es CR¹¹ o N; A⁵ es CR⁶ o N; uno de R⁵, R⁶, R⁷ y R⁸ se elige entre halógeno, ciano, alcoxi, hidroxialcoxi, haloalquilo, haloalcoxi e hidroxi y los demás se eligen con independencia entre sí entre H, halógeno, ciano, alcoxi, hidroxialcoxi, haloalcoxi e hidroxi; R⁹ es H, halógeno, hidroxi, ciano, alquilo, hidroxialquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, alquilcicloalquilo, halocicloalquilo, alquilcicloalquilalquilo, alcoxicicloalquilalquilo, halocicloalquilalquilo, cicloalquilalcoxi, cicloalquilalcoxialquilo, cicloalcoxi, cicloalcoxialquilo, halocicloalcoxi, halocicloalcoxialquilo, alquilcicloalcoxi, alquilcicloalcoxialquilo, alcoxi, alcoxialquilo, alcoxicicloalquilalquilo, dialcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, haloalcoxialcoxi, haloalcoxialcoxialquilo, arilalquilo sustituido, arilhidroxialquilo sustituido, heterocicloalquilalquilo sustituido o heteroarilalquilo sustituido, dichos arilalquilo sustituido, arilhidroxialquilo sustituido, heterocicloalquilalquilo sustituido y heteroarilalquilo sustituido están sustituidos por R³², R³³ y R³⁴; R¹⁰ es -Oₘ-(CR¹⁵R¹⁶)ₚ-(CR¹⁷R¹⁸)q-(CR¹⁹R²⁰)ʳ-R²¹; o R⁹ y R¹⁰ junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, un heterocicloalquilo sustituido, un arilo sustituido o un heteroarilo sustituido, dichos cicloalquilo sustituido, heterocicloalquilo sustituido, arilo sustituido y heteroarilo sustituido están sustituidos por R³⁵, R³⁶ y R³⁷; R¹¹ es H; R¹⁵, R¹⁷ y R¹⁹ se eligen con independencia entre H, alquilo, cicloalquilo, haloalquilo y halocicloalquilo; R¹⁶, R¹⁸ y R²⁰ se eligen con independencia entre H, hidroxi, halógeno y alquilo; o R¹⁵ y R¹⁶ junto con el átomo de carbono al que están unidos forman un cicloalquilo; o R¹⁷ y R¹⁸ junto con el átomo de carbono al que están unidos forman un cicloalquilo; o R¹⁹ y R²⁰ junto con el átomo de carbono al que están unidos forman un cicloalquilo; o R¹⁵ y R¹⁷ juntos forman un -(CH₂)ᵛ-; o R¹⁵ y R¹⁹ juntos forman un -(CH₂)ʷ-; o R¹⁷ y R¹⁹ juntos forman un -(CH₂)ˣ-; R²¹ es H, halógeno, ciano, -OR²⁵, -SR²⁵, -S(O)R²⁵, -S(O)₂R²⁵, -NR²⁵R²⁶, -NR²⁶SO₂R²⁵, -NR²⁶SO₂NR²⁵R²⁷, -NR²⁶C(O)R²⁵, -NR²⁶C(O)-NR²⁵R²⁷, -C(O)R²⁸, -C(O)NR²⁵R²⁶, cicloalquilo, heterociclo-alquilo sustituido, heteroarilo sustituido o arilo sustituido, dichos heterocicloalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido y arilo sustituido están sustituidos por R³⁸, R³⁹ y R⁴⁰; R²⁵ es H, alquilo, hidroxialquilo, carboxialquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, alquilcicloalquilo, halocicloalquilo, alquilcicloalquilalquilo, alcoxicicloalquilalquilo, halocicloalquilalquilo, cicloalquilalcoxi-alquilo, cicloalcoxialquilo, halocicloalcoxialquilo, alquilcicloalcoxialquilo, alcoxialquilo, haloalcoxialquilo, alcoxialcoxialquilo, haloalcoxialcoxialquilo, heterociclo-alquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, arilo sustituido o arilalquilo sustituido, dichos heterocicloalquil sustituido, heterocicloalquilalquilo sustituido, heteroarilo, heteroarilalquilo sustituido, arilo sustituido y arilalquilo sustituido están sustituidos por R⁴¹, R⁴² y R⁴³; R²⁶ y R²⁷ se eligen con independencia entre H, alquilo, cicloalquilo, haloalquilo y halocicloalquilo; o R¹⁵ y R²⁶ junto con el átomo de nitrógeno y el átomo de carbono al que están unidos forman un heterocicloalquilo sustituido o un heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R⁴⁷, R⁴⁸ y R⁴⁹; o R¹⁷ y R²⁶ junto con el átomo de nitrógeno y el átomo de carbono al que están unidos forman un heterocicloalquilo sustituido o un heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R⁴⁷, R⁴⁸ y R⁴⁹; o R¹⁹ y R²⁶ junto con el átomo de nitrógeno y el átomo de carbono al que están unidos forman un heterocicloalquilo sustituido o un heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R⁴⁷, R⁴⁸ y R⁴⁹; R²⁸ es H, hidroxi, alquilo, hidroxialquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, alquilcicloalquilo, halocicloalquilo, alquilcicloalquilalquilo, alcoxicicloalquil, halocicloalquilalquilo, cicloalquilalcoxi, cicloalquilalcoxialquilo, cicloalcoxi, cicloalcoxialquilo, halocicloalcoxi, halocicloalcoxialquilo, alquilcicloalcoxi, alquilcicloalcoxialquilo, alcoxi, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxi-alquilo, haloalcoxialcoxi, haloalcoxialcoxialquilo, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, arilo sustituido o arilalquilo sustituido, dichos heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido heteroarilalquilo sustituido, arilo sustituido y arilalquilo sustituido están sustituidos por R⁵⁰, R⁵¹ y R⁵²; R¹², R¹³, R¹⁴, R²², R²³, R²⁴, R²⁹, R³⁰, R³¹, R³², R³³, R³⁴, R³⁵, R³⁶, R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹ y R⁵² se eligen con independencia entre H, halógeno, hidroxi, amino, nitro, ciano, oxo, alquilo, alquilcarbonilo, alquilsulfonilo, hidroxialquilo, haloalquilo, cicloalquilo, cicloalquilalquilo, alquilcicloalquilo, halocicloalquilo, alquilcicloalquilalquilo, alquilcarbonil-amino, alquilsulfonilo, alquilsulfonilamino, alcoxicicloalquilalquilo, halocicloalquilalquilo, cicloalquilalcoxi, cicloalquilalcoxialquilo, cicloalcoxi, cicloalcoxialquilo, halocicloalcoxi, halocicloalcoxialquilo, alquilcicloalcoxi, alquilcicloalcoxialquilo, alcoxi, alcoxicarbonilo, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, haloalcoxialcoxi, halo-alcoxialcoxialquilo, cloropiridinilcarbonilo y heterocicloalquilo; n es el número cero ó 1; m es el número cero ó 1; p, q y r se eligen con independencia entre cero y 1; v y x se eligen con independencia entre 1, 2, 3 y 4; w es el número cero, 1, 2 ó 3; con la condición de que no más de dos de A², A³ y A⁴ sean N; y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011083229 | 2011-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088989A1 true AR088989A1 (es) | 2014-07-23 |
Family
ID=47297189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104439A AR088989A1 (es) | 2011-11-30 | 2012-11-27 | Derivados biciclicos de dihidroisoquinolin-1-ona |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9133158B2 (es) |
| EP (2) | EP3587401A1 (es) |
| JP (1) | JP6382108B2 (es) |
| KR (1) | KR102089927B1 (es) |
| AR (1) | AR088989A1 (es) |
| AU (1) | AU2012344041B2 (es) |
| BR (1) | BR112014013136B1 (es) |
| CA (1) | CA2850700C (es) |
| CL (1) | CL2014001389A1 (es) |
| CO (1) | CO6920296A2 (es) |
| CR (1) | CR20140229A (es) |
| DK (1) | DK2785695T3 (es) |
| EA (1) | EA035454B1 (es) |
| ES (1) | ES2811806T3 (es) |
| HR (1) | HRP20201277T1 (es) |
| HU (1) | HUE050431T2 (es) |
| IL (1) | IL232570B (es) |
| LT (1) | LT2785695T (es) |
| MA (1) | MA35664B1 (es) |
| MX (1) | MX350717B (es) |
| MY (1) | MY178867A (es) |
| PE (1) | PE20141283A1 (es) |
| PH (1) | PH12014501179B1 (es) |
| PL (1) | PL2785695T3 (es) |
| PT (1) | PT2785695T (es) |
| RS (1) | RS60660B1 (es) |
| SG (1) | SG11201402199QA (es) |
| SI (1) | SI2785695T1 (es) |
| TW (1) | TWI583678B (es) |
| UA (1) | UA112565C2 (es) |
| WO (1) | WO2013079452A1 (es) |
| ZA (1) | ZA201402908B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014173928A1 (en) * | 2013-04-23 | 2014-10-30 | Lek Pharmaceuticals D.D. | Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof |
| JP6533217B2 (ja) * | 2013-05-17 | 2019-06-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類 |
| EP3004089B1 (en) * | 2013-05-27 | 2020-05-06 | F.Hoffmann-La Roche Ag | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| MY176401A (en) | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| CR20170118A (es) * | 2014-10-08 | 2017-07-10 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| ES2724555T3 (es) * | 2014-10-15 | 2019-09-12 | Boehringer Ingelheim Int | Inhibidores de la aldosterona sintasa |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| EP3227300B1 (en) * | 2014-12-02 | 2019-06-19 | Boehringer Ingelheim International GmbH | Aldosterone synthase inhibitors |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP6545275B2 (ja) * | 2015-10-23 | 2019-07-17 | 田辺三菱製薬株式会社 | 新規含窒素芳香族複素環化合物 |
| KR20180094923A (ko) | 2015-12-24 | 2018-08-24 | 교와 핫꼬 기린 가부시키가이샤 | α, β 불포화 아미드 화합물 |
| CN110121343B (zh) | 2016-09-12 | 2023-11-03 | 整体健康 | 用作gpr120调节剂的双环化合物 |
| US10800773B2 (en) | 2016-09-12 | 2020-10-13 | Integral Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
| EP3572401B1 (en) * | 2017-01-22 | 2021-09-29 | Fujian Cosunter Pharmaceutical Co., Ltd. | Ask1 inhibitor and preparation method and use thereof |
| US11447471B2 (en) | 2017-06-23 | 2022-09-20 | Kyowa Kirin Co., Ltd. | α,β-unsaturated amide compound |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| CN109810171B (zh) * | 2017-11-21 | 2020-12-01 | 首都医科大学 | 二氢异喹啉-3-甲酰-LARGD(aa)aa,其制备,抗静脉血栓活性和应用 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| WO2020002969A1 (en) * | 2018-06-26 | 2020-01-02 | Zhejiang Vimgreen Pharmaceuticals, Ltd | Triazolotriazine derivatives as a2a receptor antagonists |
| WO2020223267A1 (en) | 2019-05-01 | 2020-11-05 | Boehringer Ingelheim International Gmbh | (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| WO2023063851A1 (en) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| WO2024061371A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州威诺森医药科技有限公司 | 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用 |
| WO2024102026A1 (en) * | 2022-11-10 | 2024-05-16 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT79699B (en) | 1983-12-22 | 1986-12-10 | Pfizer | Process for preparing quinolone inotropic agents |
| JP4361273B2 (ja) * | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| ES2442347T3 (es) * | 2006-03-29 | 2014-02-11 | Novartis Ag | Imidazoles como inhibidores de aldosterona sintasa |
| AR067585A1 (es) * | 2007-07-19 | 2009-10-14 | Schering Corp | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2430011A1 (en) * | 2009-05-15 | 2012-03-21 | Novartis AG | 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1 |
| JP2013537210A (ja) * | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
-
2012
- 2012-11-27 AR ARP120104439A patent/AR088989A1/es active IP Right Grant
- 2012-11-27 EP EP19187075.7A patent/EP3587401A1/en active Pending
- 2012-11-27 UA UAA201407120A patent/UA112565C2/uk unknown
- 2012-11-27 EP EP12797817.9A patent/EP2785695B1/en active Active
- 2012-11-27 HU HUE12797817A patent/HUE050431T2/hu unknown
- 2012-11-27 BR BR112014013136-8A patent/BR112014013136B1/pt active IP Right Grant
- 2012-11-27 EA EA201491018A patent/EA035454B1/ru not_active IP Right Cessation
- 2012-11-27 AU AU2012344041A patent/AU2012344041B2/en not_active Ceased
- 2012-11-27 PT PT127978179T patent/PT2785695T/pt unknown
- 2012-11-27 DK DK12797817.9T patent/DK2785695T3/da active
- 2012-11-27 KR KR1020147018023A patent/KR102089927B1/ko active IP Right Grant
- 2012-11-27 JP JP2014543854A patent/JP6382108B2/ja active Active
- 2012-11-27 SI SI201231822T patent/SI2785695T1/sl unknown
- 2012-11-27 PL PL12797817T patent/PL2785695T3/pl unknown
- 2012-11-27 SG SG11201402199QA patent/SG11201402199QA/en unknown
- 2012-11-27 MX MX2014005833A patent/MX350717B/es active IP Right Grant
- 2012-11-27 RS RS20200979A patent/RS60660B1/sr unknown
- 2012-11-27 LT LTEP12797817.9T patent/LT2785695T/lt unknown
- 2012-11-27 ES ES12797817T patent/ES2811806T3/es active Active
- 2012-11-27 PE PE2014000766A patent/PE20141283A1/es active IP Right Grant
- 2012-11-27 CA CA2850700A patent/CA2850700C/en active Active
- 2012-11-27 MY MYPI2014701399A patent/MY178867A/en unknown
- 2012-11-27 WO PCT/EP2012/073653 patent/WO2013079452A1/en active Application Filing
- 2012-11-29 TW TW101144851A patent/TWI583678B/zh active
- 2012-11-29 US US13/688,373 patent/US9133158B2/en active Active
-
2014
- 2014-03-31 CO CO14068498A patent/CO6920296A2/es active IP Right Grant
- 2014-04-22 ZA ZA2014/02908A patent/ZA201402908B/en unknown
- 2014-05-12 IL IL232570A patent/IL232570B/en active IP Right Grant
- 2014-05-15 CR CR20140229A patent/CR20140229A/es unknown
- 2014-05-26 PH PH12014501179A patent/PH12014501179B1/en unknown
- 2014-05-27 CL CL2014001389A patent/CL2014001389A1/es unknown
- 2014-05-27 MA MA37074A patent/MA35664B1/fr unknown
-
2020
- 2020-08-13 HR HRP20201277TT patent/HRP20201277T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
| AR087984A1 (es) | Derivados biciclicos de dihidroquinolina-2-ona | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR114083A2 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
| AR126406A2 (es) | Compuestos de tetrazolinona y su uso | |
| AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
| AR106299A1 (es) | Compuestos de piridona y fungicidas agrícolas y hortícolas que contienen dichos compuestos como ingrediente activo | |
| AR101495A1 (es) | Compuestos condensados de 11 miembros y fungicidas agrícolas / hortícolas que los contienen | |
| AR110053A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| AR109974A2 (es) | Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes | |
| AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR093820A1 (es) | Uso de 1-(ariletinil)-, 1-(heteroariletinil)-, 1-(heterocicliletinil)- y 1-(ciloalqueniletinil)-bicicloalcanoles sustituidos como principios activos contra el estres abiotico de plantas | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR087747A1 (es) | Derivados de quinolona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis | |
| AR091464A1 (es) | Compuestos biciclicos de tiofenilamida | |
| AR093821A1 (es) | Uso de 1-(ariletinil)-, 1-(heteroariletinil)-, 1-(heterocicliletinil)- y 1-(ciloalqueniletinil)-ciclohexanoles sustituidos como principios activos contra el estres abiotico de plantas | |
| AR098492A1 (es) | Derivados de purina | |
| AR097998A1 (es) | Compuestos plaguicidas | |
| AR098436A1 (es) | Compuestos tricíclicos de piperidina | |
| AR124443A1 (es) | Compuestos y composición para el tratamiento de condiciones asociadas con cgas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FG | Grant, registration |